Monte Rosa COO exercises options and sells shares

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported option-related trades in common stock.

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported option-related trades in common stock. She exercised stock options to acquire 4,351 shares at $3.98 per share and, on the same date, sold 4,351 shares at a weighted average price of $23.3808 under a Rule 10b5-1 trading plan adopted on February 19, 2026.

After these transactions, she directly holds 62,371 common shares and 26,947 stock options (right to buy) expiring on June 3, 2034. The sale transactions occurred in a price range of $22.83 to $23.71 per share.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,351 shares ($84K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Champoux Jennifer

Role Chief Operating Officer

Sold 4,351 shs ($102K)

Approx. gross sale proceeds $102K

Approx. exercise cost $17K

Approx. pre-tax spread $84K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	4,351	$0.00	$0.00
Exercise	Common Stock F1	4,351	$3.98	$17K
Sale	Common Stock F1, F2	4,351	$23.3808	$102K

Holdings After Transaction: Stock Option (Right to Buy) — 26,947 contracts (Direct); Common Stock — 62,371 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. 25% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 4,351 shares Weighted average sale price: $23.3808 per share Options exercised: 4,351 shares at $3.98 +4 more

7 metrics

Shares sold 4,351 shares Open-market sale of common stock on 2026-07-15

Weighted average sale price $23.3808 per share Multiple sale transactions between $22.83 and $23.71

Options exercised 4,351 shares at $3.98 Stock options (right to buy) exercised on 2026-07-15

Common shares held after 62,371 shares Direct common stock holdings following reported transactions

Stock options held after 26,947 options Remaining Stock Option (Right to Buy) position after exercise

Option expiration date 2034-06-03 Expiration of Stock Option (Right to Buy) grant

Sale price range $22.83 to $23.71 per share Price range for multiple sale transactions on 2026-07-15

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), substantially equal monthly installments

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

""Stock Option (Right to Buy)" listed as the derivative security title."

substantially equal monthly installments financial

"The remainder vesting in 36 substantially equal monthly installments thereafter..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Monte Rosa Therapeutics (GLUE) COO Jennifer Champoux report?

She reported exercising stock options for 4,351 shares at $3.98 and selling 4,351 common shares at a weighted average of $23.3808 on July 15, 2026. The transactions were executed under a Rule 10b5-1 trading plan.

At what prices did Monte Rosa Therapeutics (GLUE) COO sell her shares?

The 4,351 Monte Rosa common shares were sold at a weighted average price of $23.3808 per share. Individual trades occurred in multiple transactions at prices ranging from $22.83 to $23.71, according to the reported footnote disclosure.

How many Monte Rosa Therapeutics (GLUE) shares does the COO hold after these trades?

Following the reported transactions, Jennifer Champoux directly holds 62,371 Monte Rosa Therapeutics common shares. She also retains 26,947 stock options (right to buy) as of the same date, providing additional potential future equity exposure if exercised.

What stock options did the Monte Rosa Therapeutics (GLUE) COO exercise?

She exercised a Stock Option (Right to Buy) covering 4,351 underlying common shares at an exercise price of $3.98 per share. After this exercise, 26,947 options from that grant remain outstanding and are scheduled to expire on June 3, 2034.

What is the Rule 10b5-1 trading plan mentioned in the Monte Rosa (GLUE) filing?

The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted by Jennifer Champoux on February 19, 2026. Such plans pre-arrange trading instructions, allowing insiders to trade shares according to predetermined terms over time.

How do the Monte Rosa Therapeutics (GLUE) COO’s options vest over time?

For the option referenced, 25% of the underlying shares vested on May 28, 2025. The remaining shares vest in 36 substantially equal monthly installments thereafter, conditioned on Jennifer Champoux’s continued service on each respective vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Champoux Jennifer

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		M(1)		4,351	A	$3.98	66,722	D
Common Stock	07/15/2026		S(1)		4,351	D	$23.3808(2)	62,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.98	07/15/2026		M(1)			4,351	(3)	06/03/2034	Common Stock	4,351	$0	26,947	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. 25% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Phil Nickson, Attorney-in-Fact	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)